Podcasts about breakthroughs

Streamlined wish lists, clear goals, and priorities are the fuel for the most amazing breakthroughs. If you want to bypass the common source of self-sabotage-- being scattered and overwhelmed-- try this simple exercise to declutter your goals and plans! Sign up HERE to start the FREE New Year Decluttering Workshop and get an introduction to Beyond Decluttering, the life-changing new Feng Shui Decluttering Certification that will free you to zoom forward in your life: https://www.fengshuimagical.com/the_professional_decluttering_workshop  

Happy holidays from Sinica! This week, I speak with Paul Triolo, Senior Vice President for China and Technology Policy Lead at DGA Albright Stonebridge Group and nonresident honorary senior fellow on technology at the Asia Society Policy Institute's Center for China Analysis. On December 8th, Donald Trump announced via Truth Social that he would approve Nvidia H200 sales to vetted Chinese customers — a decision that immediately sparked fierce debate. Paul and I unpack why this decision was made, why it's provoked such strong reactions, and what it tells us about the future of technology export controls on China. We discuss the evolution of U.S. chip controls from the Entity List expansions under Trump's first term through the October 2022 rules and the Sullivan Doctrine, the role of David Sacks and Jensen Huang in advocating for this policy shift, whether Chinese firms will actually want to buy H200s given their heterogeneous hardware stacks and Beijing's autarky ambitions, what the Reuters report about China cracking ASML's EUV lithography code tells us about the choke point strategy, and whether selective engagement actually strengthens Taiwan's Silicon Shield or undermines it. This conversation is essential listening for understanding the strategic, technical, and political dimensions of the semiconductor competition.6:44 – What the H200 decision actually changes in the real world 9:23 – The evolution of U.S. chip controls: from Entity Lists to the Sullivan Doctrine 18:28 – How Jensen Huang and David Sacks convinced Trump 25:21 – The good-faith case for why export control advocates see H200 approval as a strategic mistake 32:12 – What H200s practically enable: training, inference, or stabilizing existing clusters 38:49 – Will Chinese companies actually buy H200s? The heterogeneous hardware reality 46:06 – The strategic contradiction: exporting 5nm GPUs while freezing tool controls at 16/14nm 51:01 – The Reuters EUV report and what it reveals about choke point technologies 58:43 – How Taiwan fits into this: does selective engagement strengthen the Silicon Shield? 1:07:26 – Looking ahead: broader rethinking of export controls or patchwork exceptions? 1:12:49 – What would have to be true in 2-3 years for critics to have been right about H200?Paying it forward: Poe Zhao and his Substack Hello China TechRecommendations: Paul: Zbig: The Life of Zbigniew Brzezinski, Amerca's Great Power Propheti by Ed Luce; Hyperdimensional Substack by Dean Ball Kaiser: Everything Is Tuberculosis by John Green; The Anthropocene Reviewed by John Green; So Very Small by Thomas LevensonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Herzberg and Yu explore emerging clinical data from the 2025 meetings of the European Society For Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC), highlighting recent advancements in HER2-targeted therapies for NSCLC. Their discussion focuses on new drugs (eg, zongertinib and trastuzumab deruxtecan), their efficacy and safety profiles, and the potential for treating HER2 mutations and overexpression.

The future of apparel decorating is moving fast and if you're not ahead of the trends, your business could be playing catch-up. In this episode, we break down the must-watch innovations, hottest techniques, and game-changing products set to dominate 2026. From heat printing breakthroughs to design trends your customers will crave, we're giving you the insider scoop that others won't.Tune in because the trends wait for no one. Are you ready to lead, or will you follow?Connect with STAHLS':FacebookHeat Press for Profit Facebook GroupInstagramYouTubeTikTokLinkedin

2025 is coming to an end and Andrea and Taleesa are taking a look at what they've learned this past year as business owners in this fun episode. Join Andrea and Taleesa as they share some of the lessons they've learned from 2025, chat about new ways to grow your business while prioritizing what's important, and give you real-life tips to make 2026 your best year yet!If you enjoyed this episode please share, rate and review it! Also mentioned in today's episode: Recognizing what projects will bring you ROI 8:06Why you should be celebrating small wins 13:23Staying organized and focused with weekly meetings 17:30Creating better boundaries 25:18Links:Estie Social Suite:https://smithandcrawford.com/aesthetically-social-suite2026 Visibility Vault:https://smithandcrawford.com/visibility-vaultBenable List: https://benable.com/smithandcrawford/medspa-must-haves-little-luxuries-that-make-a-big-differenceShow transcripts: https://smithandcrawford.com/notesEmail us: hello@smithandcrawford.comJoin our newsletter: https://smithandcrawford.com/newsletterhttps://calendly.com/smithandcrawford/30-min-strategy-session?back=1&month=2024-10https://calendly.com/smithandcrawford/aesthetically-discovery-call?back=1&month=2024-08https://smithandcrawford.com/

What does it mean when 6,000 women a day enter menopause but there are only 4,100 certified clinicians to treat them?In this year end solo episode, I'm reflecting on 2025 in women's health. It was a year that felt heavy at the start personally for me after losing my mother, and globally with so much suffering and injustice. But even in all of that, women's health moved forward in meaningful ways. Not perfectly. Not fast enough. But enough that it deserves reflection.I'm covering the moments that shifted conversations this year from the FDA removing the black box warning on estrogen to new cervical cancer screening guidelines allowing self-collection HPV tests. From Addyi finally being approved for women under 65 to the release of comprehensive GSM guidelines that make genitourinary syndrome everyone's business, not just gynecologists'.And I'm getting personal about why I launched a concierge practice this year, what it taught me about the broken healthcare system, and why sexual health cannot be practiced in 10-minute appointments.Highlights:Why you're not too old for screening and what "safe exit criteria" really means.Menopause certification jumped from under 1,000 to over 4,100 practitioners in 2025.Menopause divorce vs. midlife clarity: Why hormonal chaos shouldn't decide your marriage.DARE to PLAY is a new, topical sildenafil launching in 2026 for female arousal disorder.Treating male partners reduces recurrent BV by 50% (New England Journal of Medicine).Hormone therapy for prevention: The nuanced conversation about bone health and cardiovascular risk.Why I launched a concierge practice and what it revealed about what women actually need.Thank you for being here for another year of Gyno Girl Presents: Sex, Drugs & Hormones. Your support, your messages, and your stories are what keep me going you are my why. If this year-in-review resonated with you, please share it with someone who needs to hear that they're not broken, not dramatic, and not asking for too much. And keep following the show in 2026 we've got incredible conversations lined up.Get in Touch with Me: WebsiteInstagramYoutubeSubstack

Tim McConnehey is the Founder and CEO of Izzard Inc., one of the fastest-growing publishing firms in America. A Harvard-trained AI strategist and alum of the Goldman Sachs 10,000 Small Businesses Program, he helps entrepreneurs scale smarter through AI-powered creative and operational transformation. Top 3 Value Bombs 1. AI elevates human creativity by enhancing and not replacing the emotional, structural, and strategic sides of storytelling. 2. Process clarity is the secret weapon of small business owners who want AI to meaningfully improve profit and performance. 3. Smart experimentation beats perfectionism every time; test, tweak, improve, repeat. Check out Tim's website to explore AI-powered publishing services, manuscript assessments, and author support - Izzard Ink Publishing Sponsors HighLevel - The ultimate all-in-one platform for entrepreneurs, marketers, coaches, and agencies. Learn more at HighLevelFire.com. Freedom Circle - A powerful community of entrepreneurs led by JLD. Are you ready to go from idea to income in 90-days? Visit Freedom-Circle.com to learn more.

If you've been hearing more about psychedelic therapy and wondering whether it's a genuine breakthrough for healing—or just the latest mental health trend—you're not alone. Many people feel curious, hopeful, and skeptical all at once. This conversation is meant to help you slow down, understand what the research actually shows, and think clearly about whether this path is right for you. In this episode of Love, Happiness and Success, I'm joined by psychiatrist and MDMA-assisted psychotherapist Dr. Scott Shannon, founder of Wholeness Center, the largest integrative mental health center in the U.S. Together, we talk about how psychedelic therapy works differently from conventional psychiatric treatment, why it can help disrupt rigid trauma patterns in the brain, and what researchers are learning about long-term healing—not just short-term symptom relief. We also spend time on the parts of this conversation that matter just as much: the risks, the ethical boundaries, and the importance of preparation, professional support, and integration. Psychedelic therapy isn't appropriate for everyone, and it isn't something to pursue casually or without careful guidance. This episode offers a grounded, responsible look at how people can think critically about safety, readiness, and what to look for in a qualified provider. As you listen, I invite you to reflect on a few questions: What kind of healing are you actually looking for? What does feeling “better” really mean to you? And how do you decide which growth paths deserve your trust, time, and care? Episode Breakdown: 00:00 Psychedelic therapy explained: promise, research, and real risks 02:31 Why psychedelic therapy differs from traditional psychiatric medication 04:55 Trauma, brain patterns, and how psychedelic therapy disrupts stuck loops 07:00 MDMA-assisted therapy for PTSD and why healing can continue long after treatment 12:21 A paradigm shift in mental health: supporting the brain's capacity to heal 19:30 What MDMA actually does in therapy: safety, self-compassion, and trauma processing 25:47 Mystical experience, meaning, and the spiritual dimension of psychedelic therapy 30:09 Ethical concerns, safety risks, and how to evaluate psychedelic therapy providers 38:00 Preparation and integration: why psychedelic therapy is more than the experience itself If this conversation leaves you thinking about your own healing or growth, I want to be clear that Growing Self does not offer psychedelic therapy. What we do offer is thoughtful, evidence-based therapy and coaching for people who want to grow with intention and care. If you'd like, I'd love to help you think through what kind of support would actually be most helpful for you. I've created a simple, private way to do that. By answering just a few quick questions, we can help match you with the right therapist or coach for a complimentary consultation—someone who understands what you're navigating and where you'd like to go next. Schedule a free consultation today. Consider it a small gift from me, and a gentle next step if you're ready for one. xoxo, Dr. Lisa Marie BobbyGrowing Self

Let us know how you enjoyed this episode!Most couples don't struggle because they don't love each other. They struggle because they were never taught how to communicate, regulate, and stay connected under stress.As I close out the year, I wanted to give you a gift. Instead of another tip or hack, I'm sharing the patterns and lessons I saw come up again and again in my client sessions this year.These are lessons learned in the midst of busy lives and chances are, you'll recognize yourself in at least one of them.In this episode, I break down six of the biggest takeaways that helped my clients transform their marriage in 2025.If you feel stuck in the same cycles or unsure what to focus on next in your marriage, this episode will help you zoom out, reflect, and choose a more intentional path forward.Resources mentioned:Download the Marriage 360 Review to gain clarity on what areas to focus on in your marriageBook a Clarity Call if you want support for your marriageThanks for listening!Connect and send a message letting me know what you took away from this episode: @michellepurtacoaching and follow me on threads @michellepurtacoaching!If you would like to support this show, please rate and review the show, and share it with people you know would love this show too!Additional Resources:Ready to put a stop to the arguments in your marriage?  Watch this free masterclass - The #1 Conversation Married Couples Need To Have (But Aren't)Want to handle conflict with more confidence? Download this free workbook!Wanna make communication feel easy and stop feeling like roommates so you can bring back the romance and excitement into your marriage? Learn more about how coaching here!Support the show

A Christmas Day Special Celebrating the Insights, Breakthroughs, and Bold Conversations That Defined Our SeasonWelcome to this very special Christmas Day edition of the Affiliate Marketing Podcast. Throughout Season 23, we dug deep into the engines behind impactful content, questioned the role of SEO and AI algorithms in a world that still craves human connection, and spotlighted the evolution of affiliate marketing from community-driven growth to loyalty-first strategies and consumer discovery beyond the usual channels. Today's episode is a moment to look back on all we shared this season, appreciate how far we've come together, and celebrate the insights we gathered along the way. Grab a cup of something warm, settle in, and enjoy this Christmas Day Special as we wind up the season that's past and get ready for an even bigger one ahead.What You'll Hear in This Episode:The 6:1 content ratio that's reshaping digital marketing as Saurabh Singh reveals why educational content consistently outperforms promotional posts and how trust has become the new currency in affiliate marketingWhy most affiliate programs stall before they ever hit momentum with Florin Simovici's operational insights from 15 years of hands-on experience building scalable, sustainable programsThe harsh reality of building a content-first publisher from scratch as George Sullivan opens up about facing rejection after rejection and what affiliate managers misunderstand about the publisher's journeyWhy user-generated content is now the most powerful lever in affiliate growth from Dennis Yu's billion-dollar ad spend experience with brands like Nike and StarbucksHow AI-powered answer engines are capturing a quarter of global queries and what Colin Jeavons says this disruption really means for affiliate managers navigating an uncertain futureThe loyalty-building principles that turn silent affiliates into thriving communities as Alex Hitt shares why genuine connection, not higher commissions, truly drives retentionWhy most organisations stall on AI adoption with Katie King's roadmap for building strategic frameworks and embedding responsible governance before regulation arrivesHow daily payouts became the most powerful micro trust signal as the Exness team reveals their journey scaling from 18 to more than 100 countries with human-centric logicWhy platforms like Reddit are suddenly outranking traditional reviews and how Ewen Finser steered more than 100 websites through Google's volatility into the AI-driven landscapeHow to run your affiliate program ethically in the age of AI as Leanna Klyne and Lee-Ann discuss automation that stays human and what regulation might mean for your partner management.Call to ActionSeason 23 gave you the frameworks, now it's time to implement them. Whether you're rebuilding your onboarding process using Alex's white-glove approach, restructuring your content strategy around Saurabh's 6:1 ratio, or preparing your team for AI adoption using Katie's governance roadmap, the insights from this season only create value when you put them into action. Subscribe to the Affiliate Marketing Podcast so you're ready when Season 24 launches on New Year's Day with bold predictions for 2026 and conversations that push the boundaries of where affiliate and performance marketing are headed. DM Lee-Ann on LinkedIn and share what you're struggling with or want to know more about, and she'll find the right expert to get on the mic and talk us through it.Send me a text with your questions

How do you elevate your love life?Meet Anil Gupta - the Love Doctor!Anil is a world expert on relationships. He is the CEO of Love and the Breakthroughs that make it possible.He has helped singles and couples overcome the daily struggles and challenges to allow them to live very successful and fulfilled lives.He has performed his relationship and mindset workshops in over 18 countries and translated in 8 languages, with audiences of over 10,000. Anil "The Love Doctor" Gupta is a favorite speaker at every event he speaks at. He is the author of best selling book "Immediate Happiness". And is the Relationship Coach the Rich and Famous turn to for finding their true love, rebuilding parent child relationships, and transforming existing relationships to pure bliss.Listen as Anil shares:- how to achieve a richer, fuller, happier life- creating the love you desire in your life- recognising your worth- what behavioural patterns tell you- data collection during the dating stage- the 3 Gs of happiness- the requirements for a successful relationship- why so many do not succeed in relationships...and so much more!Connect with Anil:Website: https://meetanil.com/Additional Resources:FREE "Finding Love" e-book by Anil Gupta"Immediate Happiness" by Anil Gupta on Amazon"The Heart Map for Vitality" by Anil Gupta on AmazonListen to the Podcast, subscribe, leave a rating and a review:Apple: https://podcasts.apple.com/us/podcast/how-to-have-a-successful-relationship-the/id1614151066?i=1000742600303Spotify: https://open.spotify.com/episode/7jTpIF9fP9FPeBOt5fYAdN?si=yeQ_FAUQRNiM-_QxX2L1wghttps://open.spotify.com/episode/7jTpIF9fP9FPeBOt5fYAdNYouTube: https://youtu.be/wUn8hDqt8bk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Watch the full episode with Steve Judd here: https://youtu.be/cKniikzZF2wSupport this show http://supporter.acast.com/inspiredevolution. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

Host Piya Chattopadhyay speaks with The Atlantic's Toluse "Tolu" Olorunnipa and Politico's Hailey Fuchs about the revelations in Friday's partial release of the Epstein files – and how they intersect with U.S. politics, baker and writer Ruby Tandoh explains how virality shapes our appetites, Dr. Siddhartha Mukherjee discusses breakthroughs in cancer research, and novelist Gary Shteyngart explores the parallels between his dystopian new novel and life in the U.S. today.

In this episode of The AI Report, your always-on AI anchors Artie Intel and Micheline Learning break down December 2025’s wildest developments in artificial intelligence, from the latest “singularity-speed” model launches to the hot new tools quietly rewiring how humans work, create, and build businesses. They unpack the new generation of frontier models such as Claude Opus 4.5, Gemini 3, and GPT‑5.2, and explain why everyone from solo creators to Fortune 500 companies is racing to plug them into real workflows rather than just playing with demos.​ You’ll hear how AI is now helping inspect semiconductor chips with near‑perfect accuracy, acting as an autonomous “AI scientist” to hunt for discoveries, and even critiquing its own math proofs so humans can trust the numbers. The show also tours the month’s hottest tools: Runway Gen‑4 Turbo for video, Notion AI 3.0 for workspace automation, Adobe Firefly 4 for image generation, and advanced coding copilots and observability platforms that are changing how software gets shipped.​ Artie and Micheline zoom out to tackle the significant tensions of 2025’s “AI hype correction”: running out of quality training data, the rise of synthetic data, and the gap between shiny pilots and real productivity gains in the AI economy. They examine how governments are responding, with significant investments such as the U.S. Department of Energy’s Genesis Mission for AI‑powered science, and what it all means for workers, creators, and decision‑makers trying to stay ahead of the algorithm.​ If you want one tight, fast‑moving briefing that covers model wars, new tools, scientific breakthroughs, and the real risks behind the headlines, this is your must‑hear download on the state of AI at the end of 2025.​ Sponsor: This episode of The AI Report is brought to you by Amazon.com, your always‑open destination for last‑minute gifts, from smart gadgets to everyday essentials, delivered at the speed of your next great idea.  

Strategy founder and executive chairman Michael Saylor named one of CoinDesk's 50 Most Influential. Strategy founder and executive chairman Michael Saylor was named one of CoinDesk's 50 Most Influential people of 2025. He reflects on the evolution of bitcoin treasuries, from a niche corporate experiment into a global phenomenon, detailing how Strategy has moved beyond simple accumulation into a high-growth operating business centered on digital credit. Plus, his bullish case for bitcoin's growth and outlook into the asset's volatility. – For more, check out CoinDesk's 50 Most Influential article on Michael Saylor: https://www.coindesk.com/business/2025/12/12/most-influential-michael-saylor.  To see the full list, visit: ⁠https://www.coindesk.com/most-influential-2025⁠.  – Timecodes:  01:21 Michael Saylor's Bitcoin Journey 02:52 Institutional Support and Bitcoin Volatility 04:18 Bitcoin Treasury Strategies and Digital Credit 06:03 Exploring Digital Credit and Its Practicality 11:49 The Future of Bitcoin Treasury Companies 12:42 Innovations in Digital Credit Instruments 27:08 Challenges and Breakthroughs in 2025 39:16 Looking Ahead: Bitcoin's Price and Market Structure Legislation 43:29 Top Digital Assets for 2026 - Break the cycle of exploitation. Break down the barriers to truth. Break into the next generation of privacy. Break Free. Free to scroll without being monetized. Free from censorship. Freedom without fear. We deserve more when it comes to privacy. Experience the next generation of blockchain that is private and inclusive by design. Break free with Midnight, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠midnight.network/break-free⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - This episode was hosted by Jennifer Sanasie.

The 2025 NAIA Cross Country National Championships are in the books — and we're breaking it all down with the coaches who lived it.Originally streamed LIVE on YouTube on November 24, 2025, this episode is now available on all Airey Bros Radio podcast platforms as Episode 421.Recorded just days after the championship meet at Apalachee Regional Park in Tallahassee, Florida, the Airey Bros are joined by five elite NAIA head coaches to unpack team titles, podium finishes, All-American performances, heartbreak by a single point, and the moments you don't see on the results sheet.

Spiritual awakening in 2025 is changing fast. In this video, I share the top 5 spiritual lessons of 2025, including how AI can weaken intuition, why nervous system healing is essential for spiritual growth, and what it really means to trust your inner guidance during awakening.If you're experiencing a spiritual awakening, developing your intuition, or feeling overwhelmed by information, technology, or AI tools, these lessons will help you reconnect to your inner knowing in a grounded, embodied way.Sharing my top 5 Reality Check Breakthroughs I had this year. In 2025, my spiritual growth changed in ways I didn't expect... This year taught me that spiritual growth isn't linear — it's a spiral, intuition isn't something you “optimize,” and that over-reliance on AI and external guidance can quietly disconnect us from our inner knowing.In this video, I share the top 5 spiritual lessons I learned in 2025, including how intuition develops through nervous system regulation, why growth often reveals itself in strange ways, and how learning to feel safe with uncertainty is essential for spiritual awakening (and the collective chaos happening all around us) This isn't about rejecting technology — it's about discernment, embodiment, and reclaiming intuitive authority in a world that constantly pulls us outward.Lets be clear i'm not anti-AI but I SURE think it's doing something bts to our intuition if we're not careful and it's DESTROYING FREE THINKING. Let's talk about it.✨ In this video, you'll learn:Why spiritual growth happens in spirals, not straight linesHow intuition acts as your guiding post during awakeningThe hidden ways AI can suppress free thinking and intuition when used as a crutchWhy nervous system healing is foundational for intuitive developmentHow to feel safe walking with uncertainty instead of forcing answersIf you're navigating a spiritual awakening, emotional healing, intuition development, or feeling overwhelmed by information overload, this episode is for you.Before you go don't forget:

Aviation Week's James Pozzi, Lee Ann Shay, Lindsay Bjerregaard and Sean Broderick look back at 2025 and reflect on the biggest stories and breakthroughs in the MRO world. Is Parts Integrity Finally Having Its Moment? Supply Chain Integrity Coalition Shifts Gears  Rolls-Royce Unveils China MRO Joint Venture How Stability, Slots And Strategy Are Reshaping Base Maintenance Schools Say FAA Testing Hurdles Are Stifling MRO Workforce Growth

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

In this episode of The Brainy Business podcast, Melina Palmer speaks with Muriel Wilkins, author of Leadership Unblocked: The Beliefs That Limit Your Potential. Together, they delve into the often-hidden beliefs that can hinder effective leadership and personal growth. Muriel, an executive coach with over 20 years of experience, shares insights from her extensive work with C-suite leaders, revealing seven common beliefs that can create barriers to success. The conversation explores how these beliefs—such as "I need to be involved" and "I can't make a mistake"—shape our behaviors and decision-making processes. Muriel emphasizes the importance of self-awareness and shifting mindset to overcome these challenges, encouraging listeners to reflect on their own assumptions and the narratives they tell themselves. As you tune in, think about which beliefs may be holding you back and how you can reclaim your agency as a leader. In this episode: Discover the seven hidden beliefs that can limit leadership potential. Learn how to recognize the narratives that shape your experiences. Explore practical strategies for shifting mindset and overcoming barriers. Gain insights into the importance of external feedback and self-reflection. Understand how to take actionable steps toward personal and professional growth. Get important links, top recommended books and episodes, and a full transcript at thebrainybusiness.com/556. Looking to explore applications of behavioral economics further?  Learn With Us on our website. Subscribe to Melina's Newsletter, Brainy Bites.  Let's connect: Send Us a Message Follow Melina on LinkedIn The Brainy Business on YouTube The Brainy Business on Instagram

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.Staying healthy during the holidays (00:18): Discover how to protect yourself and others as a new influenza strain, holiday gatherings, and increased travel raise the risk of spreading viruses. 2025 breakthroughs and trends (04:31): Learn more about the technologies, regulations, and innovation influencing the future of clinical diagnostics. Note: Information in this post was accurate at the time of its posting.Resources"Answers From the Lab” podcast: Innovations Set to Shape the Industry in 2025Dr. Morice shares trends and predictions for 2025Mayo Clinic Minute: How to prepare for the influenza seasonMayo Clinic Minute: Wash your hands for better healthVaccines and viruses: Protecting health across generations

What if the hardest seasons in your business turned out to be the ones that set you free?  In this deeply honest episode, Marina Gregor, one of our senior business coaches sits down with Andrew Graham, a cattle producer from southwest Victoria, to explore a powerful story of resilience, family, and business transformation.  Andrew was previously burnt out, juggling operations management for a large-scale dairy business while navigating succession plans for his own family farm. Fast forward to today, and his world looks remarkably different, with a thriving cattle operation with 2,500 head, family back on the land, systems in place, and a sense of balance he never thought possible.  This episode is a conversation about what happens when you step out of survival mode and into leadership with clarity and intention. It's about letting go, backing yourself, and creating a business that truly works for you.  Together, they explore:  The messy reality of succession and how Andrew found clarity through it  How burnout showed up, and what it took to finally slow down  Why mindset, not just management, was the missing piece  What changed when Andrew started building the business around his life  The power of building a team and trusting them to lead  These small shifts might not look like much at first, but they're where real change starts. On the farm, it's the everyday choices including how you plan, how you work with others and how you set priorities that determine the outcome of the season. The same applies in leadership. Creating space to step back, adding structure to the work, trusting others to lead, and getting clear on roles and direction helped Andrew move from burnout to focus and confidence.  If you're looking to do the same, now is the time to take stock. Block time early in the new year to step off-farm and get clear on your 12-month priorities, because without space, clarity rarely comes. Need help resetting your goals for the new year ahead? Our Ultimate 2026 Planning Guide can help. It's a practical resource designed to support reflection, bring focus, and give you a framework to set clear, purposeful goals for the year ahead. Download the guide here.  Thank you Andrew for your openness, your wisdom, and your leadership. You've not only changed your business, you're lighting the way for others too. And to Marina, thank you for stepping in to lead this conversation with insight and care. Your ability to support others to reflect, share honestly, and draw out lessons that others can learn from is what makes conversations like this truly valuable.  Sincerely,   Jeremy Hutchings and the Farm Owners Academy Team 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Advances in AI are transforming both large-scale population analytics and ultra-precise, small-data insights that can guide individualized treatment. In this episode, Yves Lussier, Chair of Biomedical Informatics and Professor of Medicine, discusses the deep legacy of innovation behind modern electronic health records, the evolution of biomedical informatics, and the rise of AI techniques that extract meaning from both massive and minimal datasets. He explains how the “blessing of dimensionality” enables N-of-1 precision genomics, why counterfactual data and adversarial risks matter for large language models, and how engineered negative datasets could strengthen future AI systems. He also reflects on his entrepreneurial journey, from pioneering pen-based AI medical records in 1991 to building clinical data warehouses and founding major bioinformatics programs. Yves shares lessons on risk, career leaps, and the cultural ecosystems that fuel innovation.  Tune in and learn how cutting-edge informatics is reshaping research, care, and the future of AI-driven medicine! Resources: Connect with and follow Yves Lussier on LinkedIn. Follow the University of Utah School of Medicine on LinkedIn and visit their website!

Breakthroughs may look sudden, but nothing in God's kingdom happens by accident

Dr. Tina Kaczor and Dr. Leah Sherman discuss new diagnostic tools that can tell benign tumors from cancer in the pancreas, highlight the growing concerns over microplastics, and explore the link between ultra-processed foods and early colorectal cancer. They also highlight some amazing inventions by teenagers, like a melanoma-detection app and a skin-cancer-reducing soap. Last, they cover the benefits of hypnosis before breast cancer surgery and the health impact of commonly used chemicals in dry cleaning. This episode provides valuable insights for anyone interested in cancer prevention, early diagnosis, and overall wellness.Soap for skin cancers invented by TIME's Kid of the Year, Hemen BekeleA skin cancer detecting app invented by Richmond, VA high-schoolersThe dramatic increase in glyphosate use across the Midwest in the USAThe rising rates of cancer in young people around the worldExposure of rat fetuses to glyphosate levels led to early cancer developmentThe rising rate of glyphosate exposure over time Support the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today! Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books! Have a comment or suggestion? Email us at thecancerpod@gmail.com Follow us wherever you browse. We're always @TheCancerPod: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU!!

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Earlier this year, The Michael J. Fox Foundation hosted its 2025 Research Roundtable, “Building on Breakthroughs.” Tune into audio from this event to hear Parkinson's experts and MJFF staff discuss the latest in lifestyle medicine and treatments in the pipeline, as well as the power of advocating for Parkinson's policy.Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmiMentioned in this episode:Research will move us closer to a cure for Parkinson's — but we can't do it without you. Help us accelerate more life-changing breakthroughs by visiting michaeljfox.org/givetoresearch to donate today.

As we close out 2025, this episode of Pivot The Path is all about reflection, clarity, and momentum.In Episode 105, we recap the five biggest golf improvement lessons from the past year — what actually helped golfers play better, move better, and think smarter on the course. From understanding movement and managing the golf IQ side of the game to building trust and consistency, these are the takeaways that truly moved the needle in 2025.These are the lessons that helped golfers take ownership of their improvement — to truly Own Your SSWING — and carry that momentum into 2026.We also dive into what pivoting meant this year — how shifts in approach, coaching, and mindset shaped both our own games and the evolution of SSWING — and what those pivots tell us about where golf improvement is headed in 2026.To wrap things up, we share a look at what's next for Pivot The Path and SSWING in the year ahead, express gratitude for an incredible community of listeners and guests, and finish with simple, practical holiday stretches you can use to stay loose, mobile, and ready — even during travel, downtime, and cold weather — so you can head into the holidays moving well and feeling ready.Thank you for being here. Let's keep learning together and enjoying this incredible game we love.Shop SSWING Swag

2025 was a year of seismic shifts in tech, as AI surged into a critical growth phase with massive investments, partnerships, and global trade battles over chips. Intel and HPE restructured for the AI era, quantum computing made strides with Microsoft, Google, and Cisco advancing real-world applications, and cloud giants struck multibillion-dollar deals. Meanwhile, strategic acquisitions reshaped the landscape—Lenovo, SoftBank, Google, Qualcomm, Anthropic, and more strengthened AI, cloud, cybersecurity, and quantum capabilities—highlighting a year defined by scale, innovation, and high-stakes competition across the technology ecosystem.Time Stamps0:00 - Cold Open0:17 - Welcome to the Tech Field Day News Rundown 1:09 - AI is at an Inflection Point, Who Really Controls its Future?4:58 - Intel at a Crossroads: Layoffs, Leadership Change, and the Fight to Stay Relevant in AI9:31 - The Internet Is More Fragile Than You Think14:33 - HPE Under Pressure and on the Move20:39 - The Global AI Trade War Heats Up27:10 - Quantum Computing Is Moving From Hype to High Stakes30:55 - Cloud Wars Heat Up as Tech Giants Expand AI Infrastructure33:33 - Billion-Dollar Deals Changing and Redefining the Future of AI and Cloud37:53 - Upcoming Tech Field Day Events in 202643:30 - Thank You to our Guest Cohosts in 202545:27 - Thanks for Watching the Tech Field Day News RundownFollow our hosts ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Tom Hollingsworth⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Alastair Cooke⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stephen Foskett⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Tech Field Day ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X/Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bluesky⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Mastodon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

What happens when four hard-charging leaders shut the door, turn on the mics, and tell the unfiltered truth about business, burnout, delegation, AI, hiring, and scaling? You get one of the rawest, most practical leadership episodes we've ever released. Host Sean Meyers is joined by the Level Up + Live leadership team, Cody Schneider, Micah Harhoff, and Michael David Riley (MD), for a no-fluff, high-impact roundtable Q&A straight from our members. They tackle the REAL questions every entrepreneur is scared to ask: The first bottleneck that forced them to stop working in the business and start working on it How they're using AI without killing culture or trust When to hire (even when you “can't afford it”) How much to REALLY spend on marketing The biggest mistakes owners make when scaling too fast… or too slow Why burnout, ego, and control quietly destroy businesses The truth about proving people wrong vs. finding real purpose You'll hear real stories about missed family moments, burnout, failed businesses, delegation struggles, buy-back-your-time strategies, leadership growth, and the systems that separate hustlers from true builders. This is not a theory. This is battle-tested leadership from the trenches. And just when the conversation hits full stride… they drop a cliffhanger and announce Part 2 is coming. If you're an entrepreneur, emerging leader, or business owner who's serious about building something that lasts, this episode will hit different. Press play. Take notes. Level Up. Live better. Ready to Level Up Your Life and Business? Join our Level Up + Live Mastermind, the weekly power room for business owners and leaders hungry for clarity, accountability, and growth without sacrificing their soul in the process. Try it FREE for one month, levelupandlive.com/contact Hit play. Get uncomfortable. Live with intention. Stay in the loop; stay in the lead! Get exclusive insights on business, fitness, leadership, and community straight to your inbox! Subscribe to the Level Up + Live newsletter now Level Up + Live  Tools to Level Up! Free Resources — Level Up + Live

In this episode, Jenn Cody sits down with Jess Tergesen, the Director of Education at Strategies, for a heartfelt conversation about leadership, empowerment, and the future of beauty business education. Jess shares her unexpected journey from reluctant cosmetology student to industry leader, her 11-year tenure at a values-based team company, and her vision for transforming how beauty professionals learn and grow.Whether you're a salon owner looking to build a stronger team culture or a stylist wanting to step into leadership, this episode delivers powerful insights on creating businesses where everyone thrives.Key Topics CoveredFrom Behind the Chair to Director of Education: Jess's unconventional path into the beauty industry and why she stayed at one company for 11 yearsValues-Based Business Culture: What it really means to lead with values and how it shapes team loyalty and retentionLeadership Is Not a Title: Why everyone in your business can (and should) be a leader, regardless of their roleEmpowerment Through Self-Trust: Jess's personal definition of empowerment and the growth cycle every leader experiencesThe Future of Strategies Education: A complete breakdown of N.E.X.T. Austin 2026 and the new CoLab class formatTeam + Owner Collaboration: How shared language around numbers, leadership, and culture creates transformationFelt Experiences vs. Taught Information: Why education should be experienced, not just absorbedEpisode HighlightsOn Choosing Hair School: "I had my daughter when I was in high school and I was like, what am I going to do with my life to quickly get a job, be independent? I'm super creative and I like to talk to people. So I thought, I could be a hairstylist."On Leadership Being a Behavior, Not a Title: "Leadership is not a title. Anybody can be a leader no matter what their tenure is, no matter how long they've worked there. I believe that people can lead at each and every level."On Her Definition of Empowerment: "Empowerment comes from within. It means learning to trust yourself as a leader. It starts with humility, saying 'I don't know everything and I am willing to learn.'"On Building Shared Language: "When you're anchored in your values, when everybody knows why you're doing what you're doing, it becomes easier to coach to the behaviors that are required to hit the goals."On the New CoLab Education Format: "CoLab stands for collaborate and L.A.B. stands for Leadership, Action, and Breakthroughs. I wanted collaboration between owners and team members, and collaboration between diverse topics."What's Coming in 2026: N.E.X.T. AustinStrategies is launching a reimagined education experience March 2-4, 2026 in AuTo learn more about how Strategies can help you create more profit, fun, and growth potential for you, your business, and your team, schedule a free 60-minute strategy session: Strategies: https://www.strategies.comSalon/Spa Business Coaching: https://strategies.com/memberships/In-Person Salon/Spa Seminars: https://strategies.com/educationPodcast: https://strategies.com/podcast/Instagram: https://www.instagram.com/strategiesteam Facebook: https://www.facebook.com/strategiesOnline Education Portal: https://learning.strategies.com/The Beauty Business Strategies Podcast is designed to give salon, spa, medspa, barbershop, and lash studio owners, just like you, quick tips to make more money, inspire your team, and create world-class client experiences.

Social Media⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say hi on TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say Hi on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email List⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----If you've been stuck, doubting your worth, or drowning in regret — this episode is your wake-up call. Henry Lawrence drops a fire-filled reminder that you are not your past. You're not the failures, the shame, or the missed chances. You are potential in motion.In this soul-shifting transmission from The Positive Mindset Podcast, you'll learn:How to break free from your history and step into your powerWhy one moment of clarity can define your legacyThe spiritual truth about pressure, transformation, and becoming the diamondA guided breathwork session to lock in your highest visionThe deeper reason you're still here — and why it's not too lateClose your eyes. Breathe in. See your future self.This is the day everything shifts.

One Big Question Podcast I "“From Bandages to Breakthroughs: The Evolution of Wound Care"From bandages and guesswork to biotech, smart dressings, and data-driven healing — wound care has officially entered its innovation era.From Bandages to Breakthroughs isn't just a timeline, it's a testament to what happens when science, compassion, and technology stop playing small. We've moved beyond treating wounds to understanding healing at the cellular level — faster recoveries, better outcomes, and dignity for patients who deserve more than “good enough.”Progress didn't happen overnight. It happened because clinicians questioned old methods, researchers pushed limits, and innovators refused to accept stagnation. The future of wound care? Smarter, more personalized, and built to heal people, not just injuries.#FromBandagesToBreakthroughs #WoundCareInnovation #FutureOfHealthcare #MedicalAdvancement #HealthTech #ClinicalExcellence #HealingScience #InnovationInMedicine #NextGenHealthcare #MedTechMovement

This episode of The AI Report dives into a wild, high‑stakes week in artificial intelligence, as told by your favorite synthetic anchors, Artie Intel and Micheline Learning. From Hollywood power plays to life‑saving lab breakthroughs, the future is arriving fast, and it brought receipts. Artie and Micheline kick things off in Tinseltown, where Disney throws down a billion‑dollar AI deal with OpenAI while blasting Google over alleged copyright abuses, reshaping the rules of who gets paid when AI learns from blockbuster IP. Then they shift to Washington, D.C., breaking down President Trump’s new executive order to centralize AI regulation at the federal level, explaining why Big Tech is cheering, civil‑rights advocates are nervous, and what a “single national AI rulebook” means for startups, states, and ordinary users.​ From there, The AI Report races through the hottest new AI tools transforming business, marketing, and creative work, from always‑on email and calendar agents to video, design, and avatar platforms that let tiny teams operate like global studios. In the “wow” segment, they spotlight jaw‑dropping breakthroughs: AI‑enhanced medical imaging that spots deadly problems earlier, chip‑inspection systems that catch microscopic defects, wearable brain–computer interfaces empowering paralyzed users, and sketch‑to‑3D agents that turn simple drawings into full models.​ Whether you’re a creator, founder, policymaker, or just trying to keep up with the robots, this episode gives you the stories, stakes, and context behind the headlines, without the hype, and with just enough attitude to keep it fun.

The final Fed meeting of 2025 delivered a surprise rate cut, but the real story is how the market is reacting. In this week's Weekly Rollup, Ryan and David unpack what the new policy shift means for crypto liquidity, why regulators across the SEC, CFTC, and OCC are suddenly embracing onchain markets, and how Tom Lee's massive ETH accumulation is reshaping sentiment. We also get into Ethereum's growing momentum from ZK advancements and blob upgrades, the ZKsync Atlas rollout, Base's bridge drama with Solana, and Farcaster's pivot away from social. Plus, the rise of tokenization, new prediction market rails, and whether this week marks the first real cycle turn for Ethereum. ------

What does it take to build something genuinely new inside a $60B Enterprise? In this podcast hosted by Sid Shaik, Outshift by Cisco VP & CPO Papi Menon breaks down how product leaders can drive meaningful innovation inside massive enterprises, and why the future depends on incubating bold bets like agentic AI and quantum networking. He shares how to identify ideas worth pursuing, how to navigate internal pressure from sales and the board, and how to create strategic optionality that reshapes a company's trajectory. This is essential listening for product leaders looking to understand what high-stakes innovation actually demands.

In today's episode of Every Day Is Saturday, Sam Crowley breaks down the life-changing power of “one more rep.” Whether you're in the gym, rebuilding your confidence, growing your faith, or fighting for a dream that feels out of reach, the breakthrough never comes from the first easy steps — it comes from the rep you don't want to do. The rep that burns. The rep no one sees. The rep that defines your character. Sam shares a raw, real story from his Wolverine comeback workout and explains why that final rep becomes the moment where your identity shifts and momentum returns. You'll learn how the “one more rep mindset” applies to fitness, business, relationships, and personal transformation — and why this simple discipline separates people who stay stuck from people who change their entire life. If you need motivation, clarity, or a push to get back on track, this episode will light a fire under you. Listen now and discover the small action that leads to massive breakthroughs.

More resources? ----------------------- Watch Full Episodes in my YouTube channel! https://youtube.com/@drtjahn ---------------------- Get Your Free Copy of my book, "Podiatry Profits Book: Crafting A Seven-Figure Lifestyle Practice" to grow your podiatry practice. You just cover the shipping: https://www.podiatryprofitsbook.com ---------------------- Do you want to build your dream private practice without the hassles of insurance networks? Then schedule a FREE 45-min Strategy Session with me. We will dive to look at your current practice and I will provide you with a crystal game plan for you: https://drtjahn.com/the-profit-accelerator-session/ ---------------------- I've created this EXCLUSIVE Private Facebook Group community of like-minded podiatrists who are coming together to build their DREAM PRIVATE PRACTICE, and FREE to join!! https://www.facebook.com/groups/podiatryprofits

 ROOT & REWIRE MEMBERSHIPCONNECT WITH LORNA:---> Instagram @lorna_bingeeatingcoach---> Tiktok @lorna_bingeeatingcoach

2025 was the year love got messy...but it might be exactly what we needed to take our power back.This week, Andrea Knoche gets real about the year we just survived. From the wildest celebrity relationship highs and jaw-dropping breakups of 2025 to the behind-the-mic evolution of From Mrs. to Ms., Andrea unpacks what these stories say about our own love lives.It's a raw reflection on reinvention, self-worth, and choosing yourself as we head into 2026. If you're ready for intention over impulse, clarity over chaos, and relationships that actually align with your desires, this episode is your end-of-year reset.In this episode:1. What 2025's Biggest Celeb Breakups and Glow-Ups Reveal About Modern LoveFrom surprise engagements to long-term marriages ending, we unpack what these headline-making moments say about timing, chemistry, and the truth about relationship cycles in midlife and beyond.2. Why Reinvention Is the Real Love Story as We Head Into 2026We break down how to stop waiting for external validation, rewrite your own narrative, and choose relationships that meet your emotional standards — not societal expectations.3. How to Use the Lessons of This Year to Step Into Your Power Next YearReal talk on boundaries, emotional clarity, and self-sourced confidence so you can walk into 2026 with intention, alignment, and a whole new kind of main-character energy.And so much more...Looking for Andrea?Instagram: @from.mrs.2.msTikTok:@from.mrs.2.msWebsite: www.frommrs2ms.comEmail: Andrea@FromMrs2Ms.comYouTube: @FromMrs2Ms Hosted on Acast. See acast.com/privacy for more information.

Across industries, teams are solving massive, complex challenges — but too often, those breakthroughs stay hidden inside their organizations. The IISE Innovation Cup, sponsored by the University of Tennessee Knoxville, changes that. It gives teams a global stage to showcase measurable results, real-world impact, and the power of industrial and systems engineering in action.In this episode of Problem Solved, we take you inside the Innovation Cup- what it is, why it matters, and what great innovation truly looks like.You'll hear from: • Tom Mazzone, Innovation Cup committee member, on why the Cup exists and how it elevates ISE work • Aniket Ramekar (Mayo Clinic), on the digital door-sign project that transformed clinical workflows • Rishabh Bhandawat (Smurfit WestRock), on optimizing spare-parts inventory • Bill Harrington, Innovation Cup committee member, on the criteria that separate a good project from a great oneWhether you work in healthcare, manufacturing, supply chain, aerospace, or continuous improvement, this episode will inspire you to look at your systems in a new way — and maybe even submit your own project.Submissions for the IISE Innovation Cup are now open.Learn more about the IISE Innovation Cup.Bill Harrington's unedited interview on IISE Innovation Cup judging criteria:https://youtu.be/fHlwnq74HqwMake sure you subscribe to Problem Solved so you never miss an episode!Learn more about The Institute of Industrial and Systems Engineers (IISE)Problem Solved on LinkedInProblem Solved on YouTubeProblem Solved on InstagramProblem Solved on TikTokProblem Solved Executive Producer: Elizabeth GrimesInterested in contributing to the podcast or sponsoring an episode? Email egrimes@iise.org

From breakthrough AI diagnostics to personalized immunotherapy treatments, cancer care is undergoing a revolution that's already saving lives.Dr. Ross Levine, Chief Scientific Officer at Memorial Sloan Kettering, shares how new technologies are helping doctors detect cancer earlier, treat it more effectively, and transform what was once untreatable into manageable conditions. Whether you're navigating cancer personally or professionally, this conversation offers crucial insights into the future of medicine and why there's unprecedented hope in cancer treatment today.You can find Ross at: Website | Episode TranscriptIf you LOVED this episode, don't miss a single conversation in our Future of Medicine series, airing every Monday through December. Follow Good Life Project wherever you listen to podcasts to catch them all.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount Codes Hosted on Acast. See acast.com/privacy for more information.

Today one of the most vulnerable, challenging, and meaningful videos I've ever made... A deep dive into how you can experience breakthroughs in your running and life.   This episode is different than usual. It's a presentation I recorded while trying to run a Sub 3 hour marathon and let's just say, not everything always goes exactly according to plan. It's how we respond to these situations that matters most.   This episode has many visual examples that are better experienced while watching the video, vs listening to it. It could probabably still work as a podcast too.   After about 27 minutes something unexpected happens on this run. You can either listen to it, or fast forward 6 minutes to 33 minutes, for a detailed summary and conclusions.   Watch this full video on YouTube: https://youtu.be/_Hz1zJblJ5A      CHAPTERS: 0:00 How to Run a Breakthrough  1:26 Running Advice from Eliud Kipchoge, the GOAT 1:59 What is a Running Breakthrough 4:33 Real Examples of Running Breakthroughs 5:50 The Most Common Challenges Runners Face 7:39 Understanding Healthy Heart Rate Training 9:22 5 Ways to Calculate Your Easy & Hard Zones 10:50 How to Start Heart Rate Training 11:12 The 3 Training Dials You Must Master 11:52 Finding the Right Weekly Running Volume For You 13:54 Sample Training Week (Breakdown & Structure) 16:08 My Exact Running Watch Settings 17:06 What Running Flow Is And How to Access It 20:21 The Power of Living an Unhurried Life 21:44 How Journaling Can Improve Your Running Performance 22:37 How to Handle Running Frustrations 23:21 4 Drills to Help You Run with Ease  26:30 How to Finish Strong   32:03 Crossing the Finish Line 32:29 Marathon Recap, lessons learned 34:07 How to Transform Your Running and Life      LINKS AND TOOLS MENTIONED: ► Buy my book Running Breakthroughs and get amazing book bonuses: https://florisgierman.com  ► Buy my book on Amazon Worldwide - https://geni.us/running-breakthroughs  ► HR Training Zone Calculator: https://bit.ly/hr-calculator ► MAF 180 formula: https://philmaffetone.com/180-formula/ ► Talk Test: https://youtu.be/AoB2AMUq8Wg ► Lactate Testing: https://bit.ly/3WAbI5z ► Flow Rope: https://innerunnerstore.myshopify.com/ ► Path Projects: https://pathprojects.com/ ► Join Our Personal Best Running Coaching Program: https://www.pbprogram.com     PODCASTS SHOWN: ► Kipchoge's Advice to Race Faster, For Non-Elites: https://youtu.be/7E6TNeoOC3Y ► Courtney Dauwalter's Advice to Improve Your Running: https://youtu.be/OTgwIEAN3B4 ► Kilian Jornet's Advice to Race Faster: https://youtu.be/OJZO-t6O5Bk ► Lawrence van Lingen: Unstuck Your Running: https://youtu.be/QSv1bEWjepE ► Heido Moreno From Struggling Runner to Running Success: https://youtu.be/f5DBINpRv78 ► Wiliam Barth Reveals the Truth About Low Heart Rate Training: https://youtu.be/SrI6GmzAAy4 ► Dr. Phil Maffetone Interview by Floris Gierman about Heart Rate Training, Nutrition and Recovery: https://youtu.be/_TPrenWWK9U ► How Ayako Ran Her Best Times Over 50: https://youtu.be/DI0cOUQRU1I  ► Daniel Edwards - What If You Could Shave 1 Hour Off Your Marathon Time? - https://youtu.be/n-Sr9whnctc      YOU CAN FIND ME, COACH FLORIS GIERMAN HERE:  ► My Personal Best Running Coaching Program: https://www.pbprogram.com/  ► YouTube: https://www.youtube.com/florisgierman ► Strava: https://www.strava.com/athletes/1329785  ► Instagram: https://www.instagram.com/florisgierman  ► Extramilest: https://extramilest.com/  ► Path Projects: https://pathprojects.com/flo ► Podcast: https://extramilest.com/podcast/    Affiliate Disclosure: I may earn commissions if you purchase items via my affiliate links. "As an affiliate I earn from qualifying purchases." Affiliate links do not increase cost to you. Also, you do not need to use these links. You can also search for these same items in Amazon or on any search engine/shopping site of your choice and buy/research them that way.     ABOUT THE EXTRAMILEST SHOW: A podcast and YouTube channel where host Floris Gierman interviews world class athletes, coaches and health experts on the topic of how to become a stronger, healthier and happier athlete.     More info about our Personal Best Running Coaching Program can be found at https://www.pbprogram.com.      SUBSCRIBE and hit the bell to see new videos: https://bit.ly/Flo-YT  

In this reflective year-end episode of the Red Delta Project Podcast, Matt dives into the three biggest lessons that transformed his training, thinking, and overall well-being in 2025. These aren't quick tips or simple fitness hacks, these are the deeper, paradigm-shifting insights that came from writing Beautiful Strength, exploring the true nature of recovery, reshaping his environment, and understanding the power of emotional conditioning.You'll learn why needing lots of recovery can be a red flag rather than a badge of honor, how curating your physical and digital environment can drastically improve your habits without relying on willpower, and why emotional conditioning may be the next frontier in building a stronger, healthier, more resilient version of yourself.If you're ready to break free of the diet and exercise rat race and step into 2026 with more clarity, confidence, and control—this is an episode you won't want to miss.Plus, don't forget to follow the ongoing RDP Fitness Advent Calendar, with daily videos from December 1–24 designed to make fitness easier and far more effective.

Bill rambles about breakthroughs, a bike ride, and the valley. (00:00) - Thursday Afternoon Podcast (30:35) - Thursday Afternoon Throwback 12-4-17 - Bill rambles about la-z-boys, college playoffs, and nosy neighbors. (01:54:06) - Anything Better Podcast - NFL Week 14 Preview with Paul Virzi. Bill went 3-1 and Paul went 2-2. They talk about the weeks games as well as crazy people in public, the scene in New Orleans, and Lane Kiffin's move. SimpliSafe: This month only, take 50% off any new system. This is one of the best prices you will ever see for SimpliSafe. Go to http://www.SimpliSafe.com/BURR Helix: Take the Helix Sleep Quiz and find your perfect mattress in under two minutes. Go to http://www.HelixSleep.com/burr for 20% off sitewide.

Welcome back to another episode of Impact Theory with Tom Bilyeu! In today's episode, Tom is joined by Mason for a wide-ranging conversation just before the Thanksgiving holiday. Together, they dive deep into timely topics, exploring why the Russia-Ukraine conflict should matter to everyday Americans, the daunting prospects of America's growing national debt, and the ripple effects of foreign policy on domestic life. Tom breaks down the nuances of global alliances, the dangers and opportunities posed by rapidly advancing AI, and the ever-controversial interplay between capitalism and government intervention. The discussion also examines the limits of personal impact on massive systemic issues, the importance of meaning over money, and the real-world implications of social and political upheaval—offering insights, hard truths, and a dose of hope for listeners. Whether it's handling the economics of war, the prospects of AI superintelligence, or what keeps Tom motivated beyond financial success, this episode serves up thought-provoking commentary and practical wisdom. So grab your coffee, settle in, and get ready for a candid, insightful journey into the issues shaping our world—only on Impact Theory. Thank you to today's Sponsors: Linkedin: Post your job free at https://linkedin.com/impacttheory HomeServe: Help protect your home systems – and your wallet – with HomeServe against covered repairs. Plans start at just $4.99 a month at https://homeserve.com True Classic: Upgrade your wardrobe at https://trueclassic.com/impact Incogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impact CashApp: Download Cash App Today: https://capl.onelink.me/vFut/v6nymgjl #CashAppPod Business Wars: Follow Business Wars on the Wondery App or wherever you get your podcasts. Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact AirDoctor: Up to $300 off with code IMPACT at https://airdoctorpro.com Learn more about your ad choices. Visit megaphone.fm/adchoices